United States
Commercial since 2018 with USFDA-compliant formulations. Today we are among the top 10 manufacturers in the US market within the portfolio we operate in.
Our vision
Redefining therapeutics with precision and innovation
A business built on two engines: regulated-market partnerships abroad, and a patient-centric branded generics range at home.
Market presence
Where our medicines go
Serving markets across the U.S., Europe and emerging economies, with India as both our foundation and our newest focus.
Europe & UK
Filings underway, supported by manufacturing already aligned to the standards European authorities expect.
India
Our own range of branded generics, led by the cardio-diabetic portfolio and supported by a growing field organisation.
Emerging markets
Partnership-led supply into economies where affordability decides whether a therapy reaches a patient at all.
- 483 observations
- 0483 observationsUSFDA inspection, 2023
- people at Graviti
- 1000+people at Gravitiand still growing
- of revenue into R&D
- 8%of revenue into R&Dabove industry norm
- US manufacturer
- Top 10US manufacturerin our portfolio
Supplying the U.S., Europe, India and emerging markets.
International business
Partnering globally
Graviti's International Business division delivers high-quality, compliant pharmaceutical products globally through strategic partnerships and regulatory excellence — with world-class manufacturing aligned to USFDA and WHO-GMP standards, and agile development through to seamless commercialisation.
Global Regulatory Compliance
Our generics are manufactured in state-of-the-art facilities compliant with USFDA, WHO-GMP and other stringent authorities — safety, efficacy and quality at every step.
Wide Therapeutic Coverage
A broad portfolio across cardiovascular, diabetes, antibiotics, CNS and general health, addressing major global health challenges.
Affordable Health Solutions
Cost-efficient manufacturing and a robust supply chain let us offer high-quality medicines at accessible prices across diverse markets.
Cutting-edge R&D
Continuous investment in research produces bioequivalent generics that meet the highest standards of quality, stability and therapeutic effectiveness.
Branded generics — India
Browse the portfolioBringing global excellence home
India, the pharmacy of the world, has always been our foundation. Building on global expertise and robust manufacturing, we've launched our own range of branded generics — redefining healthcare, one brand at a time.
Therapy coverage
- CardiovascularAntihypertensives, lipid-lowering agents, antiplatelets and heart-failure therapies, formulated for once-daily adherence and stable plasma profiles.
- Diabetes CareBiguanides, DPP-4 inhibitors, SGLT2 inhibitors, sulfonylureas and their fixed-dose combinations across oral solid dosage forms.
- AntibioticsBroad and narrow-spectrum oral antibacterials, including beta-lactam combinations, macrolides and fluoroquinolones.
- Central Nervous SystemAntiepileptics, antidepressants, antipsychotics and neuropathic pain agents in immediate and modified-release forms.
- General HealthGastrointestinal, analgesic, antihistamine, respiratory and supplementation products for primary and self-care settings.
Future focus area
Innovating for tomorrow's healthcare
Graviti is committed to shaping the future of medicine with bold strides across five fronts.
Biologics & Biosimilars
Advancing complex protein therapeutics for life-altering treatments.
Precision Medicine
Employing AI and genomics for customised patient therapies.
Rare Diseases
Addressing unmet needs through novel orphan drugs.
Digital Therapeutics
Integrating technology and pharmaceuticals for holistic care.
Sustainable Practices
Innovating with eco-friendly manufacturing and green chemistry.
What that requires of us
- Sustained R&D investment above typical industry levels
- Manufacturing expansion with capacity designed for complex formats
- Automation and AI-driven process control across the plant
- Partnerships with organisations that hold the same quality bar